Orthofix reported 1Q19 revenue of USD $109.1MM, +0.4% vs. 1Q18.
- First U.S. implants of M6-C disc have taken place
- Spine growth driven by Spinal Kinetics motion preservation products
- Spine growth offset slightly by ongoing selective disruption of legacy salesforce as largest sales partners are moved into key geographies
- Trauma impacted by several large orders that were delayed from 1Q to 2Q
- Trauma grew slightly when viewed as trailing 12 months year-over-year
- Biologics product volume increased by 20%, but was offset by low-single-digit ASP decline
- fiberFUSE demineralized bone matrix released in limited launch
- Bone growth therapies (categorized as Other below) grew on strength of increased order volume, but were offset by product mix
Segment sales and growth on an as-reported basis ($MM):
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $22.9 | $20.7 | $2.2 | 10.6% |
Trauma | $23.2 | $27.5 | -$4.3 | -15.7% |
Orthobiologics | $15.7 | $14.3 | $1.4 | 9.7% |
Other * | $47.3 | $46.2 | $1.1 | 2.4% |
Total | $109.1 | $108.7 | $0.4 | 0.4% |
* Bone growth therapies
Sales by geographic region ($MM):
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $86.12 | $84.95 | $1.2 | 1.4% |
Ex-US | $23.0 | $23.8 | -$0.8 | -3.2% |
Total | $109.1 | $108.7 | $0.4 | 0.4% |
Net earnings ($MM):
1Q19 | Amount | % of Sales |
Sales | $109.1 | |
  Cost of Sales | -$23.7 | 21.7% |
  Genereal and Admin | -$20.5 | 18.8% |
  Other | -$1.11 | 1.0% |
  R & D | -$9.2 | 8.5% |
  Selling and Marketing | -$53.7 | 49.2% |
Net Earnings | $0.9 | 0.8% |
Source: Orthofix
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
Orthofix reported 1Q19 revenue of USD $109.1MM, +0.4% vs. 1Q18.
First U.S. implants of M6-C disc have taken place
Spine growth driven by Spinal Kinetics motion preservation products
Spine growth offset slightly by ongoing selective disruption of legacy salesforce as largest sales partners are moved into key geographies
...
Orthofix reported 1Q19 revenue of USD $109.1MM, +0.4% vs. 1Q18.
- First U.S. implants of M6-C disc have taken place
- Spine growth driven by Spinal Kinetics motion preservation products
- Spine growth offset slightly by ongoing selective disruption of legacy salesforce as largest sales partners are moved into key geographies
- Trauma impacted by several large orders that were delayed from 1Q to 2Q
- Trauma grew slightly when viewed as trailing 12 months year-over-year
- Biologics product volume increased by 20%, but was offset by low-single-digit ASP decline
- fiberFUSE demineralized bone matrix released in limited launch
- Bone growth therapies (categorized as Other below) grew on strength of increased order volume, but were offset by product mix
Segment sales and growth on an as-reported basis ($MM):
1Q19 | 1Q18 | $ Chg | % Chg | |
Spine | $22.9 | $20.7 | $2.2 | 10.6% |
Trauma | $23.2 | $27.5 | -$4.3 | -15.7% |
Orthobiologics | $15.7 | $14.3 | $1.4 | 9.7% |
Other * | $47.3 | $46.2 | $1.1 | 2.4% |
Total | $109.1 | $108.7 | $0.4 | 0.4% |
* Bone growth therapies
Sales by geographic region ($MM):
Geographic Region | 1Q19 | 1Q18 | $ Chg | % Chg |
US | $86.12 | $84.95 | $1.2 | 1.4% |
Ex-US | $23.0 | $23.8 | -$0.8 | -3.2% |
Total | $109.1 | $108.7 | $0.4 | 0.4% |
Net earnings ($MM):
1Q19 | Amount | % of Sales |
Sales | $109.1 | |
  Cost of Sales | -$23.7 | 21.7% |
  Genereal and Admin | -$20.5 | 18.8% |
  Other | -$1.11 | 1.0% |
  R & D | -$9.2 | 8.5% |
  Selling and Marketing | -$53.7 | 49.2% |
Net Earnings | $0.9 | 0.8% |
Source: Orthofix
Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.